Specialized in liquid pharmaceuticals: Blow-Fill-Seal (BFS) technology and Nasal Spray.

Read More


Your partner in bringing medical innovation to the market.

Read More

About Curida

Highly skilled Development and Manufacturing Organization with ambitions.

Read More

Contact Curida

Pharmaceutical Development or Manufacturing needs?

Contact Us

Operational Excellence in Pharmaceuticals since 1974

Curida is a Contract Development and Manufacturing Organization (CDMO) within the Pharmaceutical industry, based in Norway.

Curida has core competency in state-of-the-art manufacturing of Liquid Pharmaceuticals based on sterile unit-dose Blow-Fill-Seal (BFS) technology and Nasal Spray. The development expertise covers the full service for the development of nasal drug products, and experience on operational excellence is spanning more than 40 years. Curida has produced BFS products since 1989 and offers over three decades of know-how in this technology. Customers range from small start-ups and early stage Biotech companies to Big Pharma.

Curida is a part of an exciting and growing life science sector in Norway, and our vision is to be the National Centre for Industrialization of Medical Innovation. Curida is an active partner and member of Oslo Cancer Cluster.

Latest News

Curida and PCI Biotech have entered into a manufacturing agreement

Published: 01 Jul 2016

The pharmaceutical Contract Development and Manufacturing Organization Curida has entered into a manufacturing agreement with the Norwegian biotech company PCI Biotech. Curida will manufacture Amphinex, the lead product candidate from PCI Biotech. Amphinex is currently undergoing international clinical trials for […]

Read More

Curida achieves ISO 13485 certification

Published: 28 Jun 2016

Curida reaches yet another milestone with an achievement of ISO 13485 certification. One of our customers, a global Medical Device company, is pursuing new markets in Asia, where the ISO certification is defined as required by the local authorities. An […]

Read More